Characteristics of the patients with inflammatory bowel disease (IBD) and controls
| IBD | Controls | |
|---|---|---|
| Number | 174 | 89 |
| Sex | ||
| Male | 77 | 39 |
| Female | 97 | 50 |
| Median age (range) (y) | ||
| Male | 40.5 (20–77) | 36 (21–64) |
| Female | 37 (17–69) | 35 (20–61) |
| Ulcerative colitis | 91 | |
| Crohn’s disease | 83 | |
| Duration of disease (range) (y) | 9.01 (0.3–40) | |
| Receiving oral 5-ASA treatment | 144 | |
| Sulphasalazine (Salazopyrin) | 40 | |
| pH dependent release mesalazine (Asacol) | 8 | |
| Slow release mesalazine (Pentasa) | 28 | |
| Olsalazine (Dipentum) | 62 | |
| Concurrent use of oral steroids | 13 | |
| Concurrent use of azathioprine with/without steroids | 13 | |
| Enema therapy only (5-ASA or steroid) | 6 | |
| Receiving no maintenance therapy (5-ASA) | 18 | |
| History of intestinal resection | 18 | |
| Proctocolectomy | 12 | |
| Terminal ileum or a part of small bowel | 6 | |
| Disease parameters—median (range) | ||
| Haemoglobin (12–17 g/dl) | 12.5 (8.5–16.2) | |
| Platelet count (150–350 × 103/mm3) | 162 (158–678) | |
| Harvey Bradshaw index | 2 (0–11) | |
| Serum C-reactive protein | 3.27 (3.27–54.40) |
5-ASA, 5-aminosalicylic acid.